BCR-ABL1 plays a key role in the pathogenesis of chronic myeloid leukemia (CML), and it
has been investigated as a druggable target of tyrosine kinase inhibitors (TKIs) over two …

Neoplastic expansion of myeloid cells is associated with specific genetic changes that lead
to chronic activation of signaling pathways, as well as altered metabolism. It has become …

The mammalian target of rapamycin (mTOR) is one target of BCR‐ABL fusion gene of
chronic myeloid leukemia (CML). Moreover, it drives a compensatory route to Imatinib …

A series of substituted benzoylamino-2-[(4-benzyl) thio]-1, 3, 4-thiadiazoles has been
discovered as potent Abl tyrosine kinase inhibitors. Molecular docking simulations on the …

Bosutinib (SKI-606) is an orally active Src and Abl kinase inhibitor presently in Phase III trials
for treatment of chronic myelogenous leukaemia (CML), and in Phase II trials for treatment of …

Resistance of chronic myeloid leukemia (CML) to tyrosine kinase inhibitor imatinib mesylate
(IM) is most often due to point mutations in the Bcr-Abl fusion gene. T315I mutation (resulting …

Peripheral T-cell lymphomas not otherwise specified (PTCL/NOS) are very aggressive
tumors characterized by consistent aberrant expression of platelet-derived growth factor …

Y-box binding protein 1 (YBX1) is involved in the multi-tumor occurrence and development.
However, the regulation of YBX1 in lung tumorigenesis and the underlying mechanisms …

The tyrosine kinase inhibitor imatinib mesylate (IM) set new standards in the treatment of
chronic myeloid leukemia (CML). However, emergence of resistance to IM became a major …

Bosutinib (SKI-606) is an orally available, once-daily, dual Src and Abl kinase inhibitor with
promising clinical potential in first-, second-, and third-line treatment of chronic myeloid …